From the Guidelines
Liposomal amphotericin B is preferred over conventional amphotericin B due to its reduced nephrotoxicity and similar efficacy.
Key Differences
- Nephrotoxicity: Liposomal amphotericin B has been shown to have less nephrotoxic potential compared to conventional amphotericin B 1, 2, 3.
- Efficacy: Both formulations have similar clinical and microbiological efficacy, with liposomal amphotericin B allowing for higher doses and improved antifungal effectivity 3.
- Dosing: The optimal dose of liposomal amphotericin B has not been determined, but a dose of 4-6 mg/kg daily is recommended 2.
- Toxicity: Conventional amphotericin B is associated with dose-limiting toxicities, including infusion-related reactions and nephrotoxicity, which are reduced with liposomal formulations 4.
Clinical Considerations
- Patient Selection: Liposomal amphotericin B is preferred for patients who are at high risk of nephrotoxicity or have pre-existing renal dysfunction 1, 2.
- Monitoring: Patients receiving liposomal amphotericin B should be monitored for renal function and adverse events, although the risk of nephrotoxicity is lower compared to conventional amphotericin B 3.
- Alternative Agents: Other antifungal agents, such as azoles and echinocandins, may be considered as alternatives to amphotericin B formulations, depending on the specific clinical scenario and patient factors 1, 4.
From the Research
Difference between Liposomal and Conventional Amphotericin B
The main differences between liposomal and conventional amphotericin B are:
- Reduced toxicity: Liposomal amphotericin B has fewer infusion-related adverse events and less nephrotoxicity compared to conventional amphotericin B 5, 6, 7, 8, 9
- Improved efficacy: Liposomal amphotericin B has been shown to be more effective than conventional amphotericin B in some studies, particularly in patients with disseminated histoplasmosis and AIDS 6, 9
- Pharmacokinetics: Liposomal amphotericin B has nonlinear pharmacokinetics, with higher than dose-proportional increases in exposure, and is rapidly and extensively distributed after single and multiple doses 6
- Indications: Liposomal amphotericin B is indicated for the treatment of documented fungal infections in patients failing conventional amphotericin B or with renal impairment, as well as for empirical therapy in febrile neutropenic patients 5, 6
Key Features of Liposomal Amphotericin B
- Lipid composition: Liposomal amphotericin B is a unilamellar vesicle composed of amphotericin B and phospholipid 8
- Mechanism of action: Liposomal amphotericin B works by binding to ergosterol in fungal cell membranes, causing an increase in membrane permeability and cell death 6, 8
- Clinical efficacy: Liposomal amphotericin B has been shown to be effective in the treatment of various fungal infections, including candidiasis, aspergillosis, and histoplasmosis 6, 7, 9
Comparison with Conventional Amphotericin B
- Infusion-related events: Liposomal amphotericin B has fewer infusion-related adverse events compared to conventional amphotericin B 5, 6, 7, 8, 9
- Nephrotoxicity: Liposomal amphotericin B has less nephrotoxicity compared to conventional amphotericin B 5, 6, 7, 8, 9
- Cost: Liposomal amphotericin B is more expensive than conventional amphotericin B 5, 6